Skip to main content
. 2018 Aug 7;9(61):31832–31841. doi: 10.18632/oncotarget.25835

Figure 2. LEE011 and ruxolitinib inhibit growth by blocking cell cycle progression and STAT signalling respectively.

Figure 2

(A) Western blot showing that LEE011 blocks CDK4/6 phosphorylation of Rb and the subsequent expression of cyclin E2. Cells were treated with their respective LEE011 IC50 concentrations and harvested 3 and 9 h after. (B) RT-qPCR results of mRNA harvested from NKYS cells that were either transfected with control and EZH2 WT plasmids after 24 h. Relative fold change of EZH2 and CCND1 mRNA levels were obtained by normalising to control cells. Differences were determined to be statistically significant (n = 3, * p<0.05, ** p< 0.01, one-tailed student’s t-test). (C) NKYS, NK-S1 and KHYG cells were treated with 200 nM ruxolitinib and harvested after 3, 6, 9 and 12 h later. Blots shown for each cell line are representative blots from the same experiment, among two other independent biological replicates.